News
SLRX
2.480
-1.98%
-0.050
BRIEF-Salarius Pharmaceuticals Presents Sp-3164 Preclinical Data At The Inaugural Molecular Glue Drug Development Summit
Reuters · 01/27 14:13
HIVE, VUZI and IONQ are among pre market gainers
Seeking Alpha · 01/23 13:37
SLRX, CNET and WISA among mid-day movers
Seeking Alpha · 01/20 18:18
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 01/20 17:31
APPH, SLRX and TOUR are among pre market gainers
Seeking Alpha · 01/20 13:10
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 01/20 13:05
Why Netflix Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Benzinga · 01/20 12:55
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 01/19 21:30
Salarius Pharmaceuticals To Present SP-3164 Targeted Protein Degrader Preclinical Data At The Inaugural Molecular Glue Drug Development Summit
Benzinga · 01/19 13:44
APPH, SLRX and ARBK among mid-day movers
Seeking Alpha · 01/12 17:57
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 01/12 17:31
NMTR and SLRX among healthcare movers
Seeking Alpha · 01/05 15:30
BRIEF-Salarius Pharmaceuticals Issues New U.S. Patent For Next Gen Targeted Protein Degraders
Reuters · 01/05 14:07
Salarius Pharmaceuticals Announces Issuance Of New U.S. Patent For Next-Generation Targeted Protein Degraders
Benzinga · 01/05 13:11
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 01/05 13:05
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 01/02 21:30
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 12/30/2022 21:32
FUTU, TIGR and PALI among mid-day gainers and losers
Seekingalpha · 12/30/2022 17:43
Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session
Benzinga · 12/30/2022 17:28
More
Webull provides a variety of real-time SLRX stock news. You can receive the latest news about Salarius Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About SLRX
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical need. In addition, the Company is also developing treatments for cancers caused by dysregulated gene expression. The Company is developing two classes of drugs that address gene dysregulation: epigenetic drugs and targeted protein degraders. The Company’s technologies have the potential to work in both liquid and solid tumors. The Company’s pipeline consists of two compounds: seclidemstat (SP-2577), which is a small molecule that inhibits the epigenetic enzyme lysine specific demethylase 1 (LSD1); SP-2577 uses a reversible mechanism to inhibit LSD1’s enzymatic and scaffolding properties and thereby treat and prevent cancer progression, and SP-3164, which is a cereblon binding molecular glue and has a development path in hematological cancer and potential in solid tumors.